Benitec Biopharma’s $18 Million Stock Offering

Proskauer advised Benitec Biopharma on the transaction. Benitec Biopharma (Nasdaq: BNTC), a development-stage, gene therapy-focused, biotechnology company, closed its recent capital raise. The aggregate gross proceeds to Benitec from...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here